

Coverage criteria updates for select benefits of Government of Northwest Territories (GNWT) health benefit programs

Effective June 12, 2017, the Government of Northwest Territories (GNWT) will apply new quantity edits to ensure coverage criteria are met for the following drug products for clients under the Seniors (Group 60), Specified Disease Conditions (Group 21992) and Métis Health Benefit (Group 19866) programs. The Exception Approval process cannot be used for these products to apply for coverage beyond the coverage criteria defined in the table below.

Quantity criteria

Molecule strength/form	Coverage criteria
Dimenhydrinate 15 mg Tablet	Limited to 810 tablets per 30 day period
Dimenhydrinate 50 mg Tablet	Limited to 240 tablets per 30 day period
Dimenhydrinate 100 mg Tablet	Limited to 120 tablets per 30 day period

Please note that only the following products are currently affected:

Dimenhydrinate 50 mg Tablet – Limit of 240 tablets per 30 day period

DIN	Product description
00363766	Apo-Dimenhydrinate 50 mg Tablet
02377179	Exact Anti-Nauseant 50 mg Tablet
00013803	Gravol 50 mg Tablet
00399779	Nauseatol 50 mg Tablet
00021423	Teva-Diminate 50 mg Tablet
00605786	Travel Aid 50 mg Tablet

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

